Trial Sub Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

– At Week 26, 81% of patients in Phase 3 PaTHway Trial with chronic post-surgical hypoparathyroidism, the most common cause of this disease, achieved independence from conventional therapy while maintaining normocalcemia following treatment with TransCon PTH – Post-surgical patients treated with TransCon PTH self-reported significant improvements in disease-related symptoms, physical functioning, and daily life compared to those on placebo – Results for post-surgical patients (n=70) comparable t ....

New Jersey , United States , Baden Wüberg , Redwood City , Ascendis Pharma , Aimee Shu , Endocrinology Medical Sciences At Ascendis Pharma , Clinical Development , European Union , American Thyroid Association , Item Short Form Survey , Vice President , Endocrinology Medical Sciences , Hypoparathyroidism Patient Experience Scale , Trial Sub Analysis , About Ascendis Pharma , Palo Alto , Conventional Therapy , American Thyroid Association , Clinical Trial Data , Treatment Option , Ormal Serum Calcium Levels , Patients With Chronic ,